Why Moderna's Cancer Vaccine Matters to Investors

Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.

ETF Trends • Sep 2, 2026

New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly diagnosed and relapsed/refractory (R/R) lymphoma. PET/CT scans serve as the standard tool for assessing treatment response in lymphoma, but their performance is limited, with positive predictive value (PPV) reported as low as 50%.

Business Wire • Sep 1, 2026

Natera & Angiex Partner to Evaluate AGX101 Response With Signatera

NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.

Zacks Investment Research • Aug 28, 2026

Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen®, the world's leading breast cancer organization. Together, the organizations aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera's SignateraTM MRD test is supported by more than 185 peer-reviewed publications across multiple cancer types, including.

Business Wire • Aug 28, 2026

Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new Signatera collaboration with Angiex, Inc., a privately held biotech company developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs). Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and.

Business Wire • Aug 27, 2026

Billionaire Stanley Druckenmiller's Top Holding Is Up 37% This Year. Is the Market Pricing in the Full Story?

Billionaire investor Stanley Druckenmiller holds an $865 million position in Natera. Shares in the diagnostics company have surged over 37% year to date.

The Motley Fool • Aug 20, 2026

Natera Supports Kupando Trial to Advance ctDNA Monitoring in Cancer

NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and characterize response to KUP-101.

Zacks Investment Research • Aug 17, 2026

13F Season: Where Wall Street's Smart Money is Betting

Quarterly 13F disclosures offer individual investors an irreplaceable window into the playbooks of market-moving institutions.

Zacks Investment Research • Aug 17, 2026

Natera Spotlights Record Signatera Volumes, Raises Outlook at Canaccord Conference

Natera NASDAQ: NTRA Chief Financial Officer Mike Brophy said the company delivered strong second-quarter momentum across its women's health, oncology and organ health businesses, citing record Signatera volumes, continued revenue and average selling price strength, improved gross margins and narrowing losses while maintaining elevated investment levels.

MarketBeat • Aug 15, 2026

Natera, Inc. (NTRA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

Natera, Inc. (NTRA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

Seeking Alpha • Aug 13, 2026